Cargando…

A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies

BACKGROUND: The objective of this study was to evaluate the outcomes, mortality and toxicity associated with piperacillin-tazobactam (PT) and the addition of vancomycin (VM) to the empirical treatment of febrile neutropenic cancer patients. METHOD: A retrospective study on adult febrile neutropenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirkhazi, Mansoor, Sarriff, Azmi, Aziz, Noorizan Abd, Almana, Fatma, Arafat, Osama, Shorman, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649947/
https://www.ncbi.nlm.nih.gov/pubmed/29147417
http://dx.doi.org/10.14740/wjon867w
_version_ 1783272640660635648
author Sirkhazi, Mansoor
Sarriff, Azmi
Aziz, Noorizan Abd
Almana, Fatma
Arafat, Osama
Shorman, Mahmoud
author_facet Sirkhazi, Mansoor
Sarriff, Azmi
Aziz, Noorizan Abd
Almana, Fatma
Arafat, Osama
Shorman, Mahmoud
author_sort Sirkhazi, Mansoor
collection PubMed
description BACKGROUND: The objective of this study was to evaluate the outcomes, mortality and toxicity associated with piperacillin-tazobactam (PT) and the addition of vancomycin (VM) to the empirical treatment of febrile neutropenic cancer patients. METHOD: A retrospective study on adult febrile neutropenic patients who were admitted between September 2008 and May 2013 with solid tumor malignancies was conducted at King Fahad Specialist Hospital Dammam, Saudi Arabia. RESULTS: Out of 86 febrile neutropenic patients, 60 patients were treated with PT group and 26 patients were with PT + VM group. The two groups were comparable in terms of outcome, mortality, nephrotoxicities and hepatotoxicities. The median duration of neutropenia in PT treatment group was 4 days (range 1 - 10) in the female and 7 days (range 1 - 13) in males while in PT + VM 6 days (range 1 - 5) in female and 7.5 days (range 1 - 6) in male with significance P = 0.007. There was no significant difference in terms of duration of fever and length of stay between the two treatment groups. There were no deaths reported during treatment in both groups. In PT, the microbial eradication was 27/40 (67.5%) patients (14/27 (51.9%) of female and 13/27 (48.1%) of male)), whereas it was 13/40 (32.5%) patients (9/13 (69.2%) of female and 4/13 (30.8%) of male)) in PT + VM group. Overall, there was no significant difference in terms of microbiological eradication between the two groups (OR: 1.22; 95% CI: 0.486 - 3.072; X(2) stat: 0.182; P = 0.67). Response to therapy in clinically defined infections was higher 16/23 (69.56%) in PT treatment group than 7/23 (30.44%) in PT + VM group. But there was no significant difference between the two treatment groups in terms of clinically defined infections (OR: 1.013; 95% CI: 0.359 - 2.862; X(2) stat: 0.001; P = 0.98). There was no significant difference in renal and liver functions between the two groups in terms of serum creatinine level and clearance, alkaline phosphate and alanine tranferase and gama glutamyl tranferase. The most commonly isolated organisms were Escherichais coli (eighteen isolates), Staphylococcus aureus (seven isolates), Streptococcus spp (six isolates) and Klebsiella pneumonia (four isolates). The overall success rate was similar in both treatment arms and treatment was well tolerated, with no severe adverse reactions reported. CONCLUSION: Although the addition of VM might provide an additional value for coverage of gram-positive pathogens. This study demonstrates that there was no significant difference in terms of response rate in both treatment groups, which could be due to the low local methicillin-resistant Staphylococcus aureus (MRSA) rates and other resistant gram-positive organisms at our institution, stressing the importance of local antibiograms in developing empirical neutropenic fever protocols.
format Online
Article
Text
id pubmed-5649947
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-56499472017-11-16 A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies Sirkhazi, Mansoor Sarriff, Azmi Aziz, Noorizan Abd Almana, Fatma Arafat, Osama Shorman, Mahmoud World J Oncol Original Article BACKGROUND: The objective of this study was to evaluate the outcomes, mortality and toxicity associated with piperacillin-tazobactam (PT) and the addition of vancomycin (VM) to the empirical treatment of febrile neutropenic cancer patients. METHOD: A retrospective study on adult febrile neutropenic patients who were admitted between September 2008 and May 2013 with solid tumor malignancies was conducted at King Fahad Specialist Hospital Dammam, Saudi Arabia. RESULTS: Out of 86 febrile neutropenic patients, 60 patients were treated with PT group and 26 patients were with PT + VM group. The two groups were comparable in terms of outcome, mortality, nephrotoxicities and hepatotoxicities. The median duration of neutropenia in PT treatment group was 4 days (range 1 - 10) in the female and 7 days (range 1 - 13) in males while in PT + VM 6 days (range 1 - 5) in female and 7.5 days (range 1 - 6) in male with significance P = 0.007. There was no significant difference in terms of duration of fever and length of stay between the two treatment groups. There were no deaths reported during treatment in both groups. In PT, the microbial eradication was 27/40 (67.5%) patients (14/27 (51.9%) of female and 13/27 (48.1%) of male)), whereas it was 13/40 (32.5%) patients (9/13 (69.2%) of female and 4/13 (30.8%) of male)) in PT + VM group. Overall, there was no significant difference in terms of microbiological eradication between the two groups (OR: 1.22; 95% CI: 0.486 - 3.072; X(2) stat: 0.182; P = 0.67). Response to therapy in clinically defined infections was higher 16/23 (69.56%) in PT treatment group than 7/23 (30.44%) in PT + VM group. But there was no significant difference between the two treatment groups in terms of clinically defined infections (OR: 1.013; 95% CI: 0.359 - 2.862; X(2) stat: 0.001; P = 0.98). There was no significant difference in renal and liver functions between the two groups in terms of serum creatinine level and clearance, alkaline phosphate and alanine tranferase and gama glutamyl tranferase. The most commonly isolated organisms were Escherichais coli (eighteen isolates), Staphylococcus aureus (seven isolates), Streptococcus spp (six isolates) and Klebsiella pneumonia (four isolates). The overall success rate was similar in both treatment arms and treatment was well tolerated, with no severe adverse reactions reported. CONCLUSION: Although the addition of VM might provide an additional value for coverage of gram-positive pathogens. This study demonstrates that there was no significant difference in terms of response rate in both treatment groups, which could be due to the low local methicillin-resistant Staphylococcus aureus (MRSA) rates and other resistant gram-positive organisms at our institution, stressing the importance of local antibiograms in developing empirical neutropenic fever protocols. Elmer Press 2015-02 2015-02-14 /pmc/articles/PMC5649947/ /pubmed/29147417 http://dx.doi.org/10.14740/wjon867w Text en Copyright 2015, Sirkhazi et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sirkhazi, Mansoor
Sarriff, Azmi
Aziz, Noorizan Abd
Almana, Fatma
Arafat, Osama
Shorman, Mahmoud
A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title_full A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title_fullStr A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title_full_unstemmed A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title_short A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies
title_sort comparative study of piperacillin-tazobactam with and without vancomycin as empirical therapy for febrile neutropenic patients with solid tumor malignancies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649947/
https://www.ncbi.nlm.nih.gov/pubmed/29147417
http://dx.doi.org/10.14740/wjon867w
work_keys_str_mv AT sirkhazimansoor acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT sarriffazmi acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT aziznoorizanabd acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT almanafatma acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT arafatosama acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT shormanmahmoud acomparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT sirkhazimansoor comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT sarriffazmi comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT aziznoorizanabd comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT almanafatma comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT arafatosama comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies
AT shormanmahmoud comparativestudyofpiperacillintazobactamwithandwithoutvancomycinasempiricaltherapyforfebrileneutropenicpatientswithsolidtumormalignancies